AUSTRALIAN PAEDIATRIC SURVEILLANCE UNIT
ANNUAL REPORT, 2008 AND 2009
Yvonne Zurynski, Elizabeth Davey, Elizabeth J Elliott

Background

National active surveillance of rare diseases of childhood, including infectious and vaccine preventable diseases, genetic disorders, childhood injuries and mental health conditions is conducted by the Australian Paediatric Surveillance Unit (APSU). The study of communicable and vaccine-preventable diseases is supported in part by the Department of Health and Ageing through its communicable diseases program. In 2008 and 2009, APSU conducted national surveillance for the following infectious diseases or vaccine preventable conditions:

• acute flaccid paralysis (AFP): a major clinical presentation of poliomyelitis;¹
• acute rheumatic fever (ARF): occurs due to group A streptococcal (GAS) infection and repeat GAS infections, if not treated, may lead to heart valve damage and rheumatic heart disease;²
• congenital cytomegalovirus infection: a leading cause of congenital abnormality in Australia;³
• congenital rubella: an extremely rare condition leading to birth defects;⁴
• perinatal exposure to HIV: the most frequently reported source of HIV infection in Australian children;⁵
• neonatal herpes simplex virus (HSV) infection: a very rare, but serious infection that may cause chorioretinitis, intracerebral calcification and birth defects;
• neonatal group B streptococcus (GBS) infection: the most common cause of life threatening infections in neonates;
• intussusception: the most common cause of bowel obstruction in infants and young children that has been associated with rotavirus infection and previous rotavirus vaccines;⁶,⁷
• congenital and neonatal varicella: a rare infection that may result in birth defects.⁸

• severe complications of varicella: a range of rare but serious complications; genotyping of samples will inform future vaccine and policy development;⁸ and
• severe complications of influenza infection: complications such as pneumonia, encephalitis, myocarditis, rhabdomyolysis, disseminated coagulopathy, transverse myelitis, polyneuritis and Guillain-Barré syndrome have a significant burden among children aged less than 15 years.⁹

Methods

The APSU study protocols are developed with collaborating investigators and/or institutions that have expertise in each of the conditions studied. Detailed protocols including case definitions for each condition under surveillance and contact details of the expert investigators for each condition are available at www.apsu.org.au The APSU sends monthly report cards listing the conditions under surveillance to approximately 1,300 paediatricians and child health clinicians around Australia. Report cards are returned whether the clinician has a case to report or not, and the rate of returned report cards provides a measure of participation. In 2009 approximately 80% of clinicians chose to receive and respond to the APSU report card via e-mail. All reported cases are followed-up by a questionnaire requesting de-identified data on the child’s clinical presentation, treatment and short-term outcome. Clinicians were asked to return all questionnaires by fax as soon as children who met criteria for severe complications of influenza were identified during 2008 surveillance for seasonal influenza and during 2009 surveillance for seasonal and pandemic influenza.

The APSU aims to provide epidemiological information that is representative of the Australian child population and maximal case ascertainment is a high priority. Despite a representative mailing list (92% of all paediatricians in active clinical practice in Australia participate in monthly surveillance) and high response rates (average 96% per annum since 2000), complete case ascertainment is unlikely.¹⁰ This is particularly relevant in remote communities where children have limited access to paediatricians or when hospital admission is brief.
However, for most conditions studied by the APSU no alternative national data are available to allow an estimate of completeness of ascertainment. The APSU encourages the use of complementary data sources where available and reporting by a range of specialists to maximise case identification. Reported rates for conditions ascertained through the APSU therefore represent a minimum estimate of the incidence of these conditions in the relevant Australian child populations.

To further enhance surveillance for childhood conditions where hospital stays are minimal; where biological samples are required; and where a detailed history might be needed from parents or caregivers, the APSU, in collaboration with the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, initiated and coordinates the Paediatric Active Enhanced Disease Surveillance (PAEDS) system. This is a hospital-based surveillance system reliant on active case ascertainment by specialist surveillance nurses. Since August 2007, PAEDS has operated in 4 tertiary paediatric hospitals in 4 states: New South Wales, Victoria, South Australia, and Western Australia (www.apsu.org.au)

All data are provided after review by the expert investigators responsible for each surveillance study and are accurate as at May 2010. However, it is possible that some notifications may be reclassified at a later date as additional clinical data for existing notifications, or additional notifications, are received.

**Results**

In 2008 and 2009, 1,318 and 1,340 clinicians respectively participated in the monthly surveillance of the 11 communicable or vaccine preventable diseases under surveillance. Consistent with previously reported high rates of participation by paediatricians, the report card return rate was 94% in 2008 and 91% in 2009. Enhanced data on diagnosis, clinical management and short-term outcome were available for more than 85% of all cases notified. The Table shows the number of confirmed cases ascertained in 2008 and 2009 and for the whole study period, and the reported rate per 100,000 of child population for each condition.

**Acute flaccid paralysis**

Australia reported a non-polio AFP rate of 1.5 per 100,000 children aged less than 15 years in 2008 and 1.2 per 100,000 in 2009, exceeding the World Health Organization (WHO) AFP surveillance target of 1 case per 100,000. This is due to additional cases reported via the PAEDS system developed jointly by the APSU and the National Centre for Immunisation Research and Surveillance. The most common diagnosis of non-polio AFP was Guillain-Barré syndrome (39% in 2008 and 34% in 2009). Adequate faecal specimens (2 within 14 days of onset of paralysis) were obtained for 31% of cases, which was well below the 80% WHO target. The importation of a type 1 wild poliovirus in an adult into Australia in 2007 and the continued detection of cases of wild polio internationally, highlight the need for continued national surveillance.

**Acute rheumatic fever**

Between October 2007 and December 2009 cases of ARF were reported in all states and territories of Australia, except for Tasmania, suggesting the need for a national approach to the control of ARF and rheumatic heart disease. Almost all children were born in Australia (98%); 1 child was born in New Zealand and one in Papua New Guinea. The majority of children with ARF were Aboriginal or Torres Strait Islander, however, a small number of Caucasian children were reported from 5 states (New South Wales, Victoria, South Australia, Western Australia, and Queensland). These include the southern states where ARF is not recognised as a priority. Approximately 70% of all children reported resided in small rural towns or remote areas, with approximately 30% residing in urban or suburban areas.

**Congenital cytomegalovirus infection**

Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital malformations in Australia. APSU data show that cCMV infection is not associated with maternal illness in approximately one-third of cases, and should be considered regardless of maternal history. cCMV remains under-diagnosed. Although most cases are diagnosed by urine culture, use of polymerase chain reaction for urinary screening for CMV may increase diagnostic yield. Universal neonatal hearing screening programs may also help identify new cases. The total of 159 cases confirmed by the end of 2009 includes 6 cases that were notified between 2004 and 2007, but only confirmed recently.

**Congenital rubella (with defects)**

In 2008 there were three notifications, of which one was confirmed as a case. This was a child born to an immigrant woman from India whose
<table>
<thead>
<tr>
<th>Condition</th>
<th>Date study commenced</th>
<th>Questionnaire response (%) for total study period</th>
<th>Number of confirmed cases</th>
<th>Reported rate (per 10^5)</th>
<th>Number of confirmed cases for total study period</th>
<th>Reported rate for total study period (per 10^5 per annum)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute flaccid paralysis (AFP)</td>
<td>March 1995</td>
<td>92</td>
<td>63†</td>
<td>1.5†</td>
<td>560†</td>
<td>0.9†</td>
</tr>
<tr>
<td>Congenital cytomegalovirus</td>
<td>Jan 1999</td>
<td>74</td>
<td>34</td>
<td>11.5§</td>
<td>159</td>
<td>5.5§</td>
</tr>
<tr>
<td>Acute rheumatic fever</td>
<td>October 2007</td>
<td>88</td>
<td>48</td>
<td>1.2‡</td>
<td>104</td>
<td>1.0‡</td>
</tr>
<tr>
<td>Congenital rubella (with defects)</td>
<td>May 1993</td>
<td>95</td>
<td>1</td>
<td>0.02</td>
<td>51</td>
<td>0.1†</td>
</tr>
<tr>
<td>Perinatal exposure to HIV</td>
<td>May 1993</td>
<td>87</td>
<td>36</td>
<td>12.1§</td>
<td>424</td>
<td>9.8§</td>
</tr>
<tr>
<td>Neonatal herpes simplex virus infection</td>
<td>Jan 1997</td>
<td>96</td>
<td>9</td>
<td>3.0§</td>
<td>117</td>
<td>3.4§</td>
</tr>
<tr>
<td>Neonatal B group streptococcus Infection†</td>
<td>July 2005</td>
<td>82</td>
<td>18</td>
<td>12.1†</td>
<td>150</td>
<td>18.0†</td>
</tr>
<tr>
<td>Congenital varicella</td>
<td>May 2006</td>
<td>100</td>
<td>0</td>
<td>0.0</td>
<td>2</td>
<td>0.2†</td>
</tr>
<tr>
<td>Neonatal varicella</td>
<td>May 2006</td>
<td>77</td>
<td>0</td>
<td>0.0</td>
<td>15</td>
<td>1.5†</td>
</tr>
<tr>
<td>Severe complications of varicella</td>
<td>May 2006</td>
<td>69</td>
<td>7</td>
<td>0.2†</td>
<td>30</td>
<td>0.2†</td>
</tr>
<tr>
<td>Intussusception</td>
<td>May 2007</td>
<td>80</td>
<td>69</td>
<td>12.2**</td>
<td>154</td>
<td>10.8**</td>
</tr>
<tr>
<td>Severe complications of influenza</td>
<td>July to Sep 2008</td>
<td>100</td>
<td>59</td>
<td>5.7†</td>
<td>59</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>May to Sep 2009</td>
<td>97</td>
<td>100</td>
<td>9.5†</td>
<td>100</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* All reported rates based on child population estimates published by the Australian Bureau of Statistics.13
† All cases of AFP reported via the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance system that have been classified by the Polio Expert Committee were ‘non-polio AFP’ according to World Health Organization criteria.
‡ Based on population of children aged less than 15 years.
§ Based on number of births.
|| Based on population of children aged less than 16 years.
¶ Group B streptococcus sepsis study finished in June 2008.
** Based on number of children aged 24 months or younger.
N/A Due to the limited surveillance period a reported rate was not calculated.
vaccination history could not be confirmed. Serological testing was not performed. In 2009 there were no notifications. The risk of congenital rubella remains, particularly among immigrant women born in countries with poorly developed vaccination programs, justifying continued surveillance.\(^4\) Such women should have serological testing for rubella after arrival in Australia, and vaccination when appropriate. For women with no prior rubella immunity, travel to rubella-endemic countries in the first trimester poses a risk of congenital rubella to the foetus. Perinatal exposure to HIV and HIV infection

In 2008 there were 36 perinatal exposures to HIV in Australia, and 33 in 2009. Antenatal diagnosis of the mother’s HIV infection and use of interventions including antiretroviral treatment during pregnancy, caesarean delivery and avoidance of breastfeeding, continues to minimise the risk of mother-to-child HIV transmission.\(^5\)

**Neonatal herpes simplex virus infection**

A significant number of cases of neonatal herpes simplex virus (HSV) infection continue to be confirmed, with a preponderance in females. Presentation with skin, eye and mouth disease occurred in half of confirmed cases, whereas disseminated HSV infection occurred in a quarter of confirmed cases. Among cases with disseminated infection, more than half were diagnosed with encephalitis and a third with pneumonitis. More than 20% of confirmed cases had died before notification, with almost half of these diagnosed at post-mortem examination.

**Intussusception**

The small number of cases ascertained suggests under-reporting and the APSU data will be greatly supplemented by cases identified by PAEDS. There was a small number of cases of intussusception observed in infants who received a rotavirus vaccine but a temporal association between either Rotarix\(^6\) or RotaTeq\(^6\) vaccines and intussusception could not be confirmed using APSU data alone. Accepting the limitation of under-reporting of intussusception and limited vaccination data on confirmed cases, ongoing intussusception surveillance is better justified through the PAEDS system rather than the APSU, to further explore in detail any possible relationship between the number of observed intussusception cases, the age at vaccination, dose and vaccine given.

**Neonatal and infant *Streptococcus agalactiae* (group B streptococcus) sepsis**

The number of notifications received over the total study period are consistent with other available data. Over half (59%) of the confirmed cases of *Streptococcus agalactiae* group B (GBS) sepsis had early onset disease (EOD: at younger than 8 days of age). Pre-term birth was more common in mothers of infants with late onset disease (LOD: at 8 days of age or older) than in mothers of infants with EOD (58% versus 28%). Infant death was more common in those with LOD than in those with EOD (8% versus 4%). A detailed final report is in preparation for peer review publication by the investigators for this study.

**Severe complications of varicella infection**

In 2008, 7 children hospitalised with severe complications of varicella were reported, compared with 4 cases in 2009. The complications in 2008 included septic arthritis, focal purulent collection, osteomyelitis, and ataxia, while in 2009 there were 3 cases of ataxia and one of bacteraemia. Median stay in hospital was 12.5 days in 2008 compared with 3.5 days in 2009. All of the reported children were unvaccinated and family members were the infecting contacts.

**Congenital and neonatal varicella**

There were no cases of neonatal varicella reported in 2008 and only 1 case in 2009. This was an infant born to a woman who experienced symptoms of varicella infection 1 day after delivery. The infecting contact was identified as the woman’s husband who had been told that the illness he was experiencing was not chicken pox. No cases of congenital varicella were reported in 2008 and 2009.

**Severe complications of influenza**

In 2008, influenza B was the dominant influenza type among the 59 children hospitalised with severe complications of influenza and reported to APSU. In 2009, the dominant strain was pandemic influenza H1N1 2009 among 100 children reported to APSU. A range of complications were reported with x-ray-confirmed pneumonia the most common during both years. However, in 2009 serious complications such as encephalitis and rhabdomyolysis were more common than in 2008. Admission to paediatric intensive care was more common in 2009 (38%) compared with 2008 (29%) and 7 (7%) of the reported children died in 2009 compared with only 1 child (2%)
in 2008. Vaccination for seasonal influenza was uncommon during both 2008 and 2009, even among children with pre-existing chronic disorders who were eligible for vaccination according to current recommendations.

Conclusions and future directions

APSU data contribute significantly to the national surveillance effort, providing valuable information for clinicians, policymakers and the community.\textsuperscript{10,11,16} The APSU is often the only source of national data that includes clinical and/or laboratory details, and data on both inpatients and outpatients.\textsuperscript{10,11}

After demonstrating the feasibility of the APSU to respond rapidly to an outbreak of influenza in 2007, it has conducted surveillance for seasonal influenza in 2008 and surveillance for both seasonal and pandemic influenza in 2009. The APSU will again conduct surveillance for the severe complications of influenza from June to September in 2010.

A surveillance study of juvenile respiratory papillomatosis is planned for late 2010. Respiratory papillomatosis is a rare but devastating condition in children aged less than 12 years, and is thought to be perinatally transmitted.\textsuperscript{17} Juvenile respiratory papillomatosis is difficult to treat, recurrences are common and may lead to airway obstruction. The human papillomavirus (HPV) vaccine, which protects against HPV6 and HPV11, is currently nationally recommended and it is hoped that the rates of juvenile papillomatosis among young children will reduce with increased vaccination rates.

The APSU continues to provide useful data and clinical and public health insights relating to infectious diseases in Australian children. Ongoing surveillance through the PAEDS system will continue to complement the work of the APSU, and both APSU and PAEDS provide a platform for the rapid response to potential emerging infectious diseases threatening Australian children.

Acknowledgements

The APSU wishes to acknowledge the expertise of the chief investigators for each of the conditions studied: Dr Bruce Thorley, Victorian Infectious Diseases Reference Laboratory; Prof William Rawlinson, Virology Division, Department of Microbiology, Prince of Wales Hospital, Sydney; A/Prof Cheryl Jones, The Children’s Hospital at Westmead and Discipline of Paediatrics and Child Health, University of Sydney; Ms Ann McDonald, National Centre in HIV Epidemiology and Clinical Research; Prof Lyn Gilbert, Centre for Infectious Diseases and Microbiology, Institute for Clinical Pathology and Medical Research, Westmead Hospital, Westmead NSW; Prof Robert Booy, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead, NSW; Professor Julie Bines, Department of Gastroenterology, Royal Children’s Hospital, Melbourne.

We acknowledge the important continued contribution of all paediatricians and other child health professionals who participate in surveillance studies conducted by the APSU.

APSU activities are supported by the Australian Government Department of Health and Ageing; the National Health and Medical Research Council (Enabling Grant No: 402784 and Practitioner Fellowship No: 457084, E Elliott); the Creswick Foundation (Fellowship: Y Zurynski), the Discipline of Paediatrics and Child Health and Sydney Medical School, The University of Sydney; The Children’s Hospital at Westmead, and the Royal Australasian College of Physicians. Thanks go to Ms Nicole McKay for management of APSU data and to Dr Greta Ridley for data analysis.

Author details

Yvonne Zurynski\textsuperscript{1,2} Elizabeth Davey\textsuperscript{1,2} Elizabeth J Elliott\textsuperscript{1,2,3}

1. Australian Paediatric Surveillance Unit, The Children’s Hospital at Westmead, Westmead, New South Wales
2. Discipline of Paediatrics and Child Health, The University of Sydney, New South Wales
3. The Children’s Hospital at Westmead, Westmead, New South Wales

Corresponding author: Dr Yvonne Zurynski, Assistant Director, Australian Paediatric Surveillance Unit, The Children’s Hospital at Westmead, Locked Bag 4001, WESTMEAD NSW 2145. Telephone: +61 2 9845 1202/3005. Facsimile: +61 2 9845 3082. Email: yvonnez@chw.edu.au

References


